Investors Capital Advisory Services’s AstraZeneca AZN Stock Holding History

Investors Capital Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$329K	Hold	5,463	–	–	0.06%	394
2016 Q1	$307K	Buy	5,463 +240	+5%	+$14.4K	0.06%	409
2015 Q4	$354K	Hold	5,223	–	–	0.07%	392
2015 Q3	$332K	Buy	5,223 +67	+1%	+$4.41K	0.07%	407
2015 Q2	$328K	Sell	5,156 -91	-2%	-$6.23K	0.06%	442
2015 Q1	$359K	Sell	5,247 -112	-2%	-$7.78K	0.07%	400
2014 Q4	$377K	Sell	5,359 -200	-4%	-$14.3K	0.07%	371
2014 Q3	$397K	Sell	5,559 -184	-3%	-$13.5K	0.08%	358
2014 Q2	$426K	Sell	5,743 -217	-4%	-$15.7K	0.07%	384
2014 Q1	$386K	Sell	5,960 -35	-0.6%	-$2.26K	0.08%	342
2013 Q4	$355K	Sell	5,995 -200	-3%	-$10.9K	0.08%	338
2013 Q3	$321K	Sell	6,195 -1,549	-20%	-$77.8K	0.08%	339
2013 Q2	$366K	Buy	+7,744	New	+$394K	0.11%	266

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Investors Capital Advisory Services's AZN Position: Q2 2016 in Review

Investors Capital Advisory Services held its AstraZeneca (AZN) position steady in Q2 2016 at 5,463 shares worth $329K. The position accounts for 0.06% of the portfolio, ranked #394.

Investors Capital Advisory Services first reported a position in AZN in Q2 2013 and has held it in 13 quarters since. The position peaked at $426K in Q2 2014. 398 funds tracked by Wall St. Rank hold AZN as of Q2 2016.

Investors Capital Advisory Services held 5,463 shares of AstraZeneca worth $329K as of Q2 2016.
Investors Capital Advisory Services left its AstraZeneca share count unchanged in Q2 2016.
AstraZeneca made up 0.06% of Investors Capital Advisory Services's portfolio in Q2 2016, its #394 holding.
Investors Capital Advisory Services first reported a position in AstraZeneca in Q2 2013 and has held it in 13 quarters since.
Investors Capital Advisory Services's AstraZeneca position peaked at $426K in Q2 2014.
398 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.